非酒精性脂肪性肝病 MRI 生物标志物的可重复性:NIMBLE 联盟研究
NIMBLE 1.2 前瞻性观察性单中心短期横断面研究纳入 17 例非酒精性脂肪性肝病患者,在≤7 天两次访视内用 6 台 1.5 T 与 3 T 扫描仪行标准化 MRI,中央分析测得不同日同机重复性系数:VAT 0.22 L、MRE 硬度 0.75 kPa、PDFF 1.19%(幅值重建)与 1.56%(复数重建)。
要点
- 不同日同机 MRI PDFF 重复性系数 1.19%(幅值重建)与 1.56%(复数重建),可用于区分测量误差与真实变化。
- 内脏脂肪组织重复性系数 0.22 L,二维 MRE 肝硬度 0.75 kPa。
- 作者提示 NAFLD 患者随访中 PDFF 变化超过约 1.2%–1.6%、VAT 超过 0.22 L、MRE 超过 0.75 kPa 方可视为超出测量误差。
核心结论
- 这项初步研究提示,MRI PDFF、VAT 与 MRE 应分别采用 1.2%–1.6%、0.22 L 与 0.75 kPa 的阈值来区分测量误差与 NAFLD 患者的真实变化。
研究设计与样本
- NIMBLE 1.2 为前瞻性、观察性、单中心短期横断面研究,时间范围为 2021 年 10 月至 2022 年 6 月。
- 纳入 17 例成人 NAFLD 患者(平均年龄 58 岁±8.5〔SD〕;10 例女性),按 FIB-4 指数分为晚期纤维化低、中、高可能性。
- 受试者在间隔≤7 天的两次访视中最多接受 7 次 MRI 检查,使用来自 3 家厂商的 6 台 1.5 T 与 3 T 扫描仪并执行标准化成像方案。
- 数据由独立阅片中心(加利福尼亚大学圣迭戈分校)集中分析,分析人员经培训且对临床数据设盲。
- 测量指标为 MRI 质子密度脂肪分数(PDFF)、MR 弹性成像(MRE)肝硬度与内脏脂肪组织(VAT),采用 χ2 分布与统计模型计算汇总重复性指标的点估计及 CI。
诊断标准与关键数值
- 不同日同机重复性系数:VAT 0.22 L(95%CI:0.17,0.29)。
- 不同日同机重复性系数:二维 MRE 肝硬度 0.75 kPa(95%CI:0.6,0.99)。
- 不同日同机重复性系数:MRI PDFF 幅值重建 1.19%(95%CI:0.96,1.61),复数重建 1.56%(95%CI:1.26,2.07)。
- 不同日同机重复性系数:三维 MRE 剪切模量 19.7%(95%CI:15.8,26.2)。
- 不同日同机平均测量值:PDFF 13%–14%,VAT 6.6 L,二维 MRE 硬度 3.15 kPa。
临床应用与阅片要点
- 作者提示可将 MRI PDFF 1.2%–1.6%、VAT 0.22 L、MRE 0.75 kPa 作为阈值,用于在 NAFLD 患者中区分测量误差与真实变化。
局限性
- 原文将本研究描述为初步研究。
- 原文结论使用「suggests」表述,提示上述阈值需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background There is a need for reliable noninvasive methods for diagnosing and monitoring nonalcoholic fatty liver disease (NAFLD). Thus, the multidisciplinary Non-invasive Biomarkers of Metabolic Liver disease (NIMBLE) consortium was formed to identify and advance the regulatory qualification of NAFLD imaging biomarkers. Purpose To determine the different-day same-scanner repeatability coefficient of liver MRI biomarkers in patients with NAFLD at risk for steatohepatitis. Materials and Methods NIMBLE 1.2 is a prospective, observational, single-center short-term cross-sectional study (October 2021 to June 2022) in adults with NAFLD across a spectrum of low, intermediate, and high likelihood of advanced fibrosis as determined according to the fibrosis based on four factors (FIB-4) index. Participants underwent up to seven MRI examinations across two visits less than or equal to 7 days apart. Standardized imaging protocols were implemented with six MRI scanners from three vendors at both 1.5 T and 3 T, with central analysis of the data performed by an independent reading center (University of California, San Diego). Trained analysts, who were blinded to clinical data, measured the MRI proton density fat fraction (PDFF), liver stiffness at MR elastography (MRE), and visceral adipose tissue (VAT) for each participant. Point estimates and CIs were calculated using χ2 distribution and statistical modeling for pooled repeatability measures. Results A total of 17 participants (mean age, 58 years ± 8.5 [SD]; 10 female) were included, of which seven (41.2%), six (35.3%), and four (23.5%) participants had a low, intermediate, or high likelihood of advanced fibrosis, respectively. The different-day same-scanner mean measurements were 13%-14% for PDFF, 6.6 L for VAT, and 3.15 kPa for two-dimensional MRE stiffness. The different-day same-scanner repeatability coefficients were 0.22 L (95% CI: 0.17, 0.29) for VAT, 0.75 kPa (95% CI: 0.6, 0.99) for MRE stiffness, 1.19% (95% CI: 0.96, 1.61) for MRI PDFF using magnitude reconstruction, 1.56% (95% CI: 1.26, 2.07) for MRI PDFF using complex reconstruction, and 19.7% (95% CI: 15.8, 26.2) for three-dimensional MRE shear modulus. Conclusion This preliminary study suggests that thresholds of 1.2%-1.6%, 0.22 L, and 0.75 kPa for MRI PDFF, VAT, and MRE, respectively, should be used to discern measurement error from real change in patients with NAFLD. ClinicalTrials.gov registration no. NCT05081427 © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Kozaka and Matsui in this issue.
引用
- Fowler KJ, Venkatesh SK, Obuchowski N, et al. Repeatability of MRI Biomarkers in Nonalcoholic Fatty Liver Disease: The NIMBLE Consortium. Radiology. 2023. PMID: 37815451. doi:10.1148/radiol.231092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。